Perry Andrew
Chief Commercial Officer at G1 Therapeutics, Inc.
- Sold, on record
- $55k
- Dollars the filings state
- Form 4 sales
- 5
- Latest Jul 5, 2024
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- G1 Therapeutics, Inc.Chief Commercial Officer
Sales by reason
Form 4 sales per year, every sale on record.
Timeline
- 1 Form 4 sale G1 Therapeutics, Inc.Plan not statedJan 4, 2023 2023
Sold 820 shares at $5.58 ($5k)
Perry Andrew, Chief Commercial Officer
Sold 3.7% of holdings ($123k position)21,300 shares leftFirst sale on recordFiling
- 2 Form 4 sale G1 Therapeutics, Inc.RoutineJul 5, 2023 +182 days
Sold 355 shares at $2.45 ($870)
Perry Andrew, Chief Commercial Officer
10b5-1 planSold 0.6% of holdings ($138k position)55,945 shares leftFiling
- 3 Form 4 sale G1 Therapeutics, Inc.No planJan 3, 2024 +182 days
Sold 2,413 shares at $3.12 ($8k)
Perry Andrew, Chief Commercial Officer
No 10b5-1 planSold 2.7% of holdings ($279k position)87,102 shares leftFiling
- 4 Form 4 sale G1 Therapeutics, Inc.UnusualMay 13, 2024 +131 days
Sold 8,151 shares at $4.79 ($39k)
Perry Andrew, Chief Commercial Officer
No 10b5-1 planSold 9.4% of holdings ($417k position)78,951 shares left9.9x usual sizeFiling
- 5 Form 4 sale G1 Therapeutics, Inc.No planJul 5, 2024 +53 days
Sold 1,337 shares at $2.51 ($3k)
Perry Andrew, Chief Commercial Officer
No 10b5-1 planSold 1.2% of holdings ($286k position)112,614 shares left0.8x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (5)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jul 5, 2024 | Jul 8, 2024 | G1 Therapeutics, Inc. | Chief Commercial Officer | Form 4 sale | 1,337 | $3k | 1.2% | No plan | SEC |
| May 13, 2024 | May 15, 2024 | G1 Therapeutics, Inc. | Chief Commercial Officer | Form 4 sale | 8,151 | $39k | 9.4% | Unusual | SEC |
| Jan 3, 2024 | Jan 8, 2024 | G1 Therapeutics, Inc. | Chief Commercial Officer | Form 4 sale | 2,413 | $8k | 2.7% | No plan | SEC |
| Jul 5, 2023 | Jul 7, 2023 | G1 Therapeutics, Inc. | Chief Commercial Officer | Form 4 sale | 355 | $870 | 0.6% | Routine | SEC |
| Jan 4, 2023 | Jan 5, 2023 | G1 Therapeutics, Inc. | Chief Commercial Officer | Form 4 sale | 820 | $5k | 3.7% | Plan not stated | SEC |